Intrahepatic cholangiocarcinoma patient with epidermal growth factor receptor exon 19 deletion unresponsive to Afatinib monotherapy: a case report.

Discov Oncol · 2025 · PMC11985877 · PMID 40208392

Europe PMC DOI

hedged sentence

0.1300

closest p · 2.6× alpha

0.1300

boldest claim

The sentences

showed a trendp = 0.13not close (p > 0.1)

did not reach statistical significanceno p-value reported

Similarly, in Leone's VECTIBIL trial, the addition of panitumumab showed a trend towards enhanced overall survival (OS) advantage in ICC patients (15.1 months vs 11.8 months, p = 0.13) [ 23 ], although this result did not reach statistical significance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.